This is the first longitudinal study of LMs in an RR-MS patient cohort, and the first longitudinal analysis of a correlation of LMs and several biomarkers including MRI, immune cell subsets and NfL in peripheral blood of RR-MS patients and in patients treated with an SFE. This evidence concerns the gene NEFL and myeloid sarcoma.